CML: The good, the better, and the difficult choices

Research output: Contribution to journalComment/debatepeer-review

3 Scopus citations


In this issue of Blood, Radich and colleagues from 4 cooperative groups report on the results of a randomized study of dasatinib versus imatinib as initial treatment for patients with chronic phase chronic myeloid leukemia (CML).

Original languageEnglish (US)
Pages (from-to)3866-3867
Number of pages2
Issue number19
StatePublished - Nov 8 2012
Externally publishedYes

ASJC Scopus subject areas

  • Biochemistry
  • Immunology
  • Hematology
  • Cell Biology


Dive into the research topics of 'CML: The good, the better, and the difficult choices'. Together they form a unique fingerprint.

Cite this